Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Cipla
Colorcon
Mallinckrodt
Harvard Business School
AstraZeneca
Federal Trade Commission
Cantor Fitzgerald
Deloitte
Moodys

Generated: February 18, 2018

DrugPatentWatch Database Preview

Retapamulin - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for retapamulin and what is the scope of retapamulin patent protection?

Retapamulin
is the generic ingredient in one branded drug marketed by Aqua Pharms Llc and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Retapamulin has sixty-nine patent family members in thirty-five countries.

Three suppliers are listed for this compound.
Summary for retapamulin
International Patents:69
US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 3
Bulk Api Vendors: 42
Clinical Trials: 16
Patent Applications: 375
Drug Prices:see low prices
DailyMed Link:retapamulin at DailyMed
Pharmacology for retapamulin

US Patents and Regulatory Information for retapamulin

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aqua Pharms Llc ALTABAX retapamulin OINTMENT;TOPICAL 022055-001 Apr 12, 2007 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Aqua Pharms Llc ALTABAX retapamulin OINTMENT;TOPICAL 022055-001 Apr 12, 2007 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Aqua Pharms Llc ALTABAX retapamulin OINTMENT;TOPICAL 022055-001 Apr 12, 2007 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for retapamulin

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,281,226 Pleuromutilin derivatives as antimicrobials ➤ Try a Free Trial
RE39128 Pleuromutilin derivatives as antimicrobials ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for retapamulin

Supplementary Protection Certificates for retapamulin

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2007 00052 Denmark ➤ Try a Free Trial
1028961/01 Switzerland ➤ Try a Free Trial PRODUCT NAME: RETAPAMULIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 58641 04.08.2009
C/GB07/061 United Kingdom ➤ Try a Free Trial PRODUCT NAME: RETAPAMULIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/390/001 20070524; UK EU/1/07/390/002 20070524; UK EU/1/07/390/003 20070524; UK EU/1/07/390/004 20070524
6 Finland ➤ Try a Free Trial
372 Luxembourg ➤ Try a Free Trial 91372, EXPIRES: 20220524
C042/2007 Ireland ➤ Try a Free Trial SPC042/2007: 20080415, EXPIRES: 20220523
C0057 France ➤ Try a Free Trial PRODUCT NAME: RETAPAMULIN; REGISTRATION NO/DATE IN FRANCE: EU/1/07/390/001 DU 20070524; REGISTRATION NO/DATE AT EEC: EU/1/07/390/001 DU 20070524
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Harvard Business School
Farmers Insurance
US Department of Justice
QuintilesIMS
McKinsey
Colorcon
Cerilliant
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot